ESMO 2026 has ended. This guide stays up as the record of who was there. Next: ESMO 2027, Sep 17–21, 2027 in Barcelona

MD Anderson Cancer Center at ESMO 2026

Oct 23–27, 2026 Madrid, Spain ~37k attendees Website

MD Anderson Cancer Center takes part in 59 sessions at ESMO 2026 in Madrid, and exhibits at Booth 8006. Its program focuses on molecularly guided treatment and emerging therapies across cancers. Specific topics include KRAS G12D-targeted treatment for pancreatic cancer and using circulating tumour DNA to track treatment response and residual disease.

OrganizationESMO 2026 Attendance
Cancer centre & hospitalExhibitor
Comprehensive cancer treatment and research centre of the University of Texas in Houston, Texas.
Booth
Exhibiting at Booth 8006
Poster
Fri Oct 23
13:00–15:00
A phase 2 study of emiltatug ledadotin (Emi-Le) in patients with aggressive adenoid cystic carcinoma: EMBLEM-1
ePoster session 9
Sarcoma, CNS, head & neck and rare cancers
Poster
Fri Oct 23
13:00–15:00
AI-informed novel biomarker discovery for BRAF + EGFR + PD-1 therapies in MSS, BRAFV600E metastatic colorectal cancer (mCRC)
ePoster session 2
Gastrointestinal cancersBiomarkers & precision oncology
Poster
Fri Oct 23
13:00–15:00
Cisplatin or carboplatin? A quantitative umbrella review of meta-analyses in solid tumors to inform treatment choice
ePoster session 25
Gynaecological cancersLung & thoracic cancersSarcoma, CNS, head & neck and rare cancersGenitourinary cancers
Poster
Fri Oct 23
13:00–15:00
Delineating the targetable transcriptome in cancers of unknown primary (CUP) for antibody-drug conjugates (ADC)
ePoster session 22
Gastrointestinal cancersSarcoma, CNS, head & neck and rare cancersBiomarkers & precision oncology
Poster
Fri Oct 23
13:00–15:00
Poster
Fri Oct 23
13:00–15:00
Poster
Fri Oct 23
13:00–15:00
Poster
Fri Oct 23
13:00–15:00
Poster
Fri Oct 23
13:00–15:00
Poster
Fri Oct 23
13:00–15:00
Talk
Fri Oct 23
13:30
Early-phase clinical trials
YO Mentorship session · with University of Cambridge
Talk
Fri Oct 23
14:30–14:45
Validating AI for oncology: Navigating the road to clinical implementation
Transforming oncology with generative AI and autonomous tools
Abstract
Fri Oct 23
14:32–14:37
702RO - Immune checkpoint blockade for patients with leptomeningeal metastases from non-small cell lung cancer
Rapid oral: CNS tumours
Sarcoma, CNS, head & neck and rare cancers
Poster
Fri Oct 23
15:15–16:00
Analysis of the safety, tolerability, and PK of EIK1005, a novel WRN inhibitor
Friday Poster Display session 6
Gastrointestinal cancers
Poster
Fri Oct 23
15:15–16:00
Poster
Fri Oct 23
15:15–16:00
Clonal and subclonal resistance during anti-EGFR rechallenge in metastatic colorectal cancer
Friday Poster Display session 3
Gastrointestinal cancersBiomarkers & precision oncology
Poster
Fri Oct 23
15:15–16:00
Poster
Fri Oct 23
15:15–16:00
Poster
Fri Oct 23
15:15–16:00
First-in-human trial of BGB-58067, an MTA-Cooperative PRMT5 Inhibitor, in MTAP-deficient advanced tumors
Friday Poster Display session 6
Gastrointestinal cancersLung & thoracic cancersSarcoma, CNS, head & neck and rare cancersGenitourinary cancers
Poster
Fri Oct 23
15:15–16:00
Goblet cell appendiceal adenocarcinoma is a distinct disease entity defined by LGR5/Wnt mediated oncogenesis driving an immune-excluded tumor microenvironment
Friday Poster Display session 3
Gastrointestinal cancersSarcoma, CNS, head & neck and rare cancers
Poster
Fri Oct 23
15:15–16:00
Poster
Fri Oct 23
15:15–16:00
Prevalence, prognosis, and impact on tumor microenvironment (TME) of homozygous MTAP deletion (MTAP-del) in advanced solid tumors
Friday Poster Display session 3
Gastrointestinal cancersLung & thoracic cancersGenitourinary cancersBiomarkers & precision oncology
Poster
Fri Oct 23
15:15–16:00
Safety and activity of IAM1363, a CNS penetrant HER2 TKI in participants with HER2 altered advanced cancers
Friday Poster Display session 6
Gastrointestinal cancersGynaecological cancersBreast cancerSarcoma, CNS, head & neck and rare cancersGenitourinary cancers
Chair
Fri Oct 23
16:15–17:45
Emerging therapeutic strategies in advanced prostate cancer
with OnkoZentrum Zürich
Genitourinary cancers
Talk
Fri Oct 23
17:15–17:35
New targets (ADCs, new biologies)
Emerging therapeutic strategies in advanced prostate cancer
Genitourinary cancers
Satellite
Fri Oct 23
18:45–19:10
Elacestrant in ESR1-mutant mBC: Establishing the Standard of Care
Menarini Stemline - ESR1-mutated Advanced Breast Cancer: A Transforming Treatment Landscape
Breast cancerBiomarkers & precision oncology
Chair
Sat Oct 24
08:30–10:00
Rapid oral 1: NSCLC, metastatic
with Dana-Farber Cancer Institute, Leiden University Medical Center
Lung & thoracic cancers
Abstract
Sat Oct 24
08:45–09:00
Invited Discussant LBA73, 2719RO and 2700RO
Rapid oral 1: NSCLC, metastatic
Lung & thoracic cancers
Talk
Sat Oct 24
09:10–09:30
Logistics of cellular therapy
Cellular therapy in solid tumors
Poster
Sat Oct 24
12:00–12:45
A phase 2 study of neoadjuvant cemiplimab for stage II–IV cutaneous squamous cell carcinoma (CSCC): Final analysis
Saturday Poster Display session 4
Melanoma & skin cancersSarcoma, CNS, head & neck and rare cancers
Poster
Sat Oct 24
12:00–12:45
Poster
Sat Oct 24
12:00–12:45
RNA-seq phasing spotlights secondary oncogenic mutations for clinical interpretation
Saturday Poster Display session 6
Biomarkers & precision oncology
Satellite
Sat Oct 24
13:05–13:25
KRAS G12C Biology: A Unique Oncogenic Driver With Dual Impact
Eli Lilly and Company - KRAS G12C-Mutant NSCLC Across the Disease Continuum: From Biology and Unmet Needs to Optimizing Care
Lung & thoracic cancers
Satellite
Sat Oct 24
14:00–14:15
A new chapter? The evolving role of ADCs in mCRC
Merck Healthcare KGaA - Striving for more: The cutting edge of therapeutic developments in mCRC
Gastrointestinal cancers
Chair
Sat Oct 24
14:45–16:15
Proffered paper: Developmental therapeutics
with NEXT Oncology
Abstract
Sat Oct 24
15:15–15:27
Invited Discussant 999O, 1000O and 1001O
Proffered paper: Developmental therapeutics
Chair
Sat Oct 24
16:30–18:00
Updates on myeloid neoplasms with a focus on medical oncology practice
with University of Milan
Haematological malignancies
Talk
Sat Oct 24
17:10–17:30
Current treatment landscape of AML based on a comprehensive genomic assessment
Updates on myeloid neoplasms with a focus on medical oncology practice
Haematological malignancies
Abstract
Sun Oct 25
08:30–08:35
4244RO - NeoCOAST-2: Association of ctDNA clearance with clinical outcomes in a global platform phase 2 perioperative trial
Rapid oral 1: Basic science and translational research
Biomarkers & precision oncology
Talk
Sun Oct 25
10:45–11:00
The role of the oncologist in multidimensional AI integration in cancer care
ESMO-ASCO: The evolving definition of the modern oncologist
Poster
Sun Oct 25
12:00–12:45
Poster
Sun Oct 25
12:00–12:45
Allele specific characteristics of KRASQ61 mutated gastrointestinal malignancies with clinical outcomes and transcriptomic features in pancreatic cancer
Sunday Poster Display session 3
Gastrointestinal cancersBiomarkers & precision oncology
Poster
Sun Oct 25
12:00–12:45
Chromosomal instability is associated with worse survival and an immunosuppressive tumor microenvironment in microsatellite stable colorectal cancer
Sunday Poster Display session 5
Gastrointestinal cancersBiomarkers & precision oncology
Poster
Sun Oct 25
12:00–12:45
Poster
Sun Oct 25
12:00–12:45
Organ-specific response to KRAS inhibitors in metastatic colorectal cancer
Sunday Poster Display session 5
Gastrointestinal cancers
Poster
Sun Oct 25
12:00–12:45
Poster
Sun Oct 25
12:00–12:45
Young-onset versus late-onset colorectal cancer in phase I trials: Toxicity and survival outcomes
Sunday Poster Display session 4
Gastrointestinal cancers
Satellite
Sun Oct 25
13:10–13:25
Emerging evidence in BRAFV600E-mutant mCRC
Pierre Fabre Laboratories - BRAFV600E-mutant mCRC: Precision medicine in practice
Gastrointestinal cancersBiomarkers & precision oncology
Satellite
Sun Oct 25
13:55–14:25
From the clinic: Applying precision medicine in practice
Pierre Fabre Laboratories - BRAFV600E-mutant mCRC: Precision medicine in practice · with Vall d'Hebron University Hospital, Charité – Universitätsmedizin Berlin, Peter MacCallum Cancer Centre
Gastrointestinal cancersBiomarkers & precision oncology
Abstract
Sun Oct 25
15:15–15:25
Talk
Sun Oct 25
15:30–15:50
Pathological response for the win
More cures in early melanoma
Melanoma & skin cancers
Chair
Sun Oct 25
16:30–18:00
Rapid oral: Supportive and palliative care
with The Royal Marsden, The University of Melbourne
Nursing & supportive care
Abstract
Sun Oct 25
16:45–16:55
Invited Discussant 3469RO, 3085RO and 3895RO
Rapid oral: Supportive and palliative care
Nursing & supportive care
Chair
Mon Oct 26
08:30–10:00
New targets and strategies
with University of Oxford
Chair
Mon Oct 26
08:30–10:00
Proffered paper: Supportive and palliative care
with Klinikum Ernst von Bergmann
Nursing & supportive care
Chair
Mon Oct 26
08:30–10:00
Rapid oral: AI & digital health
with Inria, University Hospital RWTH Aachen
Talk
Mon Oct 26
09:15–09:30
New small molecules
New targets and strategies
Abstract
Mon Oct 26
09:24–09:36
Invited Discussant 173RO and 282RO
Rapid oral: AI & digital health
Talk
Mon Oct 26
10:35–10:55
Biology and mechanisms of action of novel immunotherapies
From science to clinical use: Emerging systemic therapies for lung cancer
Lung & thoracic cancers
Poster
Mon Oct 26
12:00–12:45
AXL protein expression by immunohistochemistry in sarcoma subtypes: Implications for antibody-drug conjugate development
Monday Poster Display session 6
Sarcoma, CNS, head & neck and rare cancers
Poster
Mon Oct 26
12:00–12:45
Clinical prediction model for early mortality in leukemia patients following inpatient chemotherapy
Monday Poster Display session 2
Haematological malignancies
Poster
Mon Oct 26
12:00–12:45
Imneskibart (AU-007) + low-dose SC IL-2 + avelumab: Phase 2 activity in CPI-refractory advanced adenocarcinoma NSCLC
Monday Poster Display session 4
Lung & thoracic cancersSarcoma, CNS, head & neck and rare cancers
Poster
Mon Oct 26
12:00–12:45
Poster
Mon Oct 26
12:00–12:45
LINNET: A phase 2 study to evaluate lorigerlimab in participants (pts) with advanced gynecologic cancers
Monday Poster Display session 1
Gynaecological cancers
Poster
Mon Oct 26
12:00–12:45
Neoadjuvant and adjuvant tiragolumab plus atezolizumab in PD-L1-positive oral cavity squamous cell carcinoma
Monday Poster Display session 2
Sarcoma, CNS, head & neck and rare cancers
Poster
Mon Oct 26
12:00–12:45
Satellite
Mon Oct 26
13:05–13:25
Charting the Path Forward in KRAS G12C Lung Cancer
F. Hoffmann - La Roche LTD - Advancing the Frontiers of Lung Cancer Care
Lung & thoracic cancers
Talk
Mon Oct 26
14:45–15:00
Bispecific antibodies
Emerging biological agents and their role in innate immunity modulation
Chair
Mon Oct 26
14:45–16:15
Chair
Mon Oct 26
14:45–16:15
Rapid oral: Prevention, early detection and intervention
with Netherlands Cancer Institute, Medical University of Vienna
Abstract
Mon Oct 26
15:39–15:44
Abstract
Mon Oct 26
15:44–15:56
Invited Discussant 1152RO and 1153RO
Rapid oral: Prevention, early detection and intervention
Talk
Mon Oct 26
16:30–16:45
IO-based systemic therapy (incl pt selection)
IO-based systemic therapy in head and neck cancers
Sarcoma, CNS, head & neck and rare cancers
Satellite
Mon Oct 26
19:25–19:50
Managing Complexity: Sequencing HER2-Directed Therapies After Progression
Physicians' Education Resourse, LLC (PER) - Show Me the Data: HER2- Mutant NSCLC in Transition – Translating Evidence to Practice
Lung & thoracic cancersBiomarkers & precision oncology

Explore the full ESMO 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in Madrid. Leave your work email and we’ll be in touch.

Privacy

Download the full ESMO 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Find decision makers at MD Anderson Cancer Center

Tell us what you sell and we’ll find the people at MD Anderson Cancer Center most likely to buy it.

  • Who to contact
  • Their contact info
  • What to say
  • Free, no sign-up

Not affiliated with or endorsed by the European Society for Medical Oncology. Submit a correction